AEON Biopharma, Inc. (AEON)
NYSE American
Price as at 30 Sept 2026, 16:08 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
AEON Biopharma, Inc. trades at $0.29. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its AEON data?
Fundamentals for AEON come from company filings and exchange data, as listed on NYSE American; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:08 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AEON, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.